Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
The Absence Of Cd20 Messenger Rna In Recurrent Cutaneous B-Cell Lymphoma Following Rituximab Therapy, Yeshwant B. Rawal, Gerard J. Nuovo, Gwyn E. Frambach, Pierluigi Porcu, Robert A. Baiocchi, Cynthia M. Magro
The Absence Of Cd20 Messenger Rna In Recurrent Cutaneous B-Cell Lymphoma Following Rituximab Therapy, Yeshwant B. Rawal, Gerard J. Nuovo, Gwyn E. Frambach, Pierluigi Porcu, Robert A. Baiocchi, Cynthia M. Magro
School of Dentistry Faculty Research and Publications
Background: Rituximab has been used to treat relapsed low-grade or advanced non-Hodgkin's lymphoma since 1997, targeting the CD20 antigen expressed by B cells. Single-agent rituximab therapy is safe and well tolerated. Recurrences showing a loss of CD20 expression following rituximab therapy have been reported.
Methods: Four patients with CD20-positive cutaneous B-cell lymphoma received rituximab therapy with subsequent recurrences. The biopsies were assessed for cytoplasmic CD20 expression; CD20 messenger RNA was also assessed where tissue was available.
Results: Cutaneous relapses occurring within 1.5–3 months following the last dose of rituximab were CD20 negative. In three cases, subsequent relapses showed renewed expression …